Gives an overview of data on the use of sublingual and transmucosal buprenorphine for the medication-assisted treatment of opioid use disorder. Discusses the implications of utilizing medication-assisted treatment a a recovery support.
C4 -This grey literature reference is included in the Academy's Literature Collection in keeping with our mission to gather all sources of information on integration. Grey literature is comprised of materials that are not made available through traditional publishing avenues. Often, the information from unpublished resources can be limited and the risk of bias cannot be determined.
C5 - Grey Literature; Opioids & Substance Use N2 -Gives an overview of data on the use of sublingual and transmucosal buprenorphine for the medication-assisted treatment of opioid use disorder. Discusses the implications of utilizing medication-assisted treatment a a recovery support.
PY - 2016 RN - https://store.samhsa.gov/sites/default/files/SAMHSA_Digital_Download/PEP21-02-01-002.pdf T1 - Advisory: Sublingual and Transmucosal Buprenorphine for Opioid Use Disorder: Review and Update TI - Advisory: Sublingual and Transmucosal Buprenorphine for Opioid Use Disorder: Review and Update U1 - Grey Literature; Opioids & Substance Use U4 -This grey literature reference is included in the Academy's Literature Collection in keeping with our mission to gather all sources of information on integration. Grey literature is comprised of materials that are not made available through traditional publishing avenues. Often, the information from unpublished resources can be limited and the risk of bias cannot be determined.
U5 - https://store.samhsa.gov/sites/default/files/SAMHSA_Digital_Download/PEP21-02-01-002.pdf UR - https://store.samhsa.gov/sites/default/files/SAMHSA_Digital_Download/PEP21-02-01-002.pdf VL - SMA16-4938 Y1 - 2016 ER -